Two Years In, Two Thirds Got Their Faces Back

Vitiligo is an autoimmune condition in which the immune system destroys melanocytes, leaving depigmented patches. It occurs at broadly similar rates across populations. What is not similar is what it costs to have it.

On deeply pigmented skin, the contrast is absolute. A patch that is barely noticeable on someone pale is, on someone dark, visible across a room and impossible to conceal without deliberate effort. And in communities where skin tone already carries social weight, a condition that lightens patches of skin arrives loaded with meanings that have nothing to do with immunology.

The measured burden reflects that. Work on Indian vitiligo patients cites psychiatric morbidity — anxiety, depression, sleep disturbance — in roughly 25 percent of patients, and the qualitative studies in this literature include patients describing suicidal thoughts. The study I am drawing that from is small, fifty patients and qualitative in design, and I am flagging that rather than presenting it as a precise population figure. The direction is not in dispute.

This is a disease that is routinely categorized as cosmetic. It is not, and the people who call it cosmetic are generally not the ones living inside the contrast.

The ruxolitinib numbers, read properly

Ruxolitinib cream — a topical JAK inhibitor — was approved by the FDA on 18 July 2022 for non-segmental vitiligo, on the strength of the two TRuE-V trials published in the New England Journal of Medicine. TRuE-V1 enrolled 330 patients, TRuE-V2 enrolled 343, randomized 2:1 to 1.5 percent ruxolitinib cream once daily or vehicle for 24 weeks, after which everyone received the active drug through week 52.

The primary endpoint was F-VASI75 — at least 75 percent repigmentation of the face.

At week 24: 29.8 percent in TRuE-V1, 30.9 percent in TRuE-V2.

Roughly three in ten, at six months. The coverage at the time read that as modest, and if you stop reading there it is.

At week 52, once every patient had been on active drug: 52.8 percent and 48.0 percent.

At week 104, in the open-label extension: of 177 evaluable patients on continuous ruxolitinib, 117 achieved F-VASI75. That is 66.1 percent. F-VASI90 — near-complete facial repigmentation — 33.9 percent. And total-body T-VASI50, 63.8 percent.

The authors’ own conclusion is the part worth carrying: response rates increased steadily through two years without plateauing.

What that changes about the appointment

It changes what counts as failure.

A patient who uses this for four months, sees a scatter of pigment islands, and concludes it is not working has stopped somewhere around the point where the week-24 responders were still in the minority. The drug is slow because repigmentation is slow — melanocytes have to migrate in from follicular reservoirs and the edges of the patch, and that is a months-to-years process, not a weeks one.

Which means the useful question to settle before starting is not whether it works. It is how long you and your prescriber have agreed to give it, in writing, before calling it. Two years is the horizon the data supports. Nobody sets that expectation at the first appointment, and it is the single most important thing about this treatment.

The approval that has not happened

Ritlecitinib is an oral JAK inhibitor. It has FDA approval for severe alopecia areata. It has been studied in vitiligo.

As of September 2026 it is not FDA-approved for vitiligo, and a claim to the contrary has been circulating.

I am flagging it specifically because of how this plays out in practice. A patient reads that a pill has been approved for her condition, asks her prescriber for it by name, and is told no — which reads as gatekeeping rather than as an accurate statement of what the drug is licensed for. Trust goes out of the appointment and it does not come back easily.

The pipeline is genuinely active and oral JAK inhibitors in vitiligo are a real area of investigation. Approved and under investigation are different words with different consequences at a pharmacy counter.

Things that get called vitiligo and are not

Three, and the distinction matters because they are treated entirely differently.

Idiopathic guttate hypomelanosis — small, sharply defined white spots, usually a few millimeters, typically on sun-exposed shins and forearms, accumulating with age. Associated with cumulative sun exposure rather than autoimmunity. Common, harmless, and not going anywhere.

Pityriasis alba — ill-defined pale patches with a fine scale, usually on the face, mostly in children and adolescents, associated with mild eczema and dry skin. Resolves. The borders are the giveaway: vague and blending, where vitiligo is sharply demarcated.

Progressive macular hypomelanosis — confluent pale macules on the trunk, associated with Cutibacterium acnes, and treated with benzoyl peroxide and light rather than with immunomodulators. Frequently misdiagnosed, and the misdiagnosis wastes years.

A Wood’s lamp separates most of these in about ten seconds, which is worth knowing exists and worth asking for.

Ask for it before the word is used rather than after. Under a dermatoscope, vitiligo and the pale patch left by an old rash look the same — the study that checked says so in its results — and the difference between those two labels is the difference between a lifelong autoimmune diagnosis and something that fades.

This article is educational and is not a substitute for care from someone who can look at your skin. Anything new, changing, painful or spreading should be assessed rather than researched.